Papers
2
Total Citations
33
H-Index
2
About
Dr. Mazen Mislmani is a radiation oncologist whose research focuses on the use of stereotactic ablative radiotherapy (SABR) for treating gynecologic malignancies, particularly in recurrent and metastatic settings. His work has pioneered the integration of SABR with systemic chemotherapy, exploring novel treatment paradigms for patients with limited options. In a landmark Phase I trial (28 citations), Dr. Mislmani established the safety of combining carboplatin and gemcitabine chemotherapy with abdominopelvic robotic SABR for persistent or recurrent gynecologic cancers, providing a critical foundation for future combination therapies. He has also specifically characterized acute gastrointestinal toxicity following fractionated SABR for upper abdominal metastases (5 citations), offering essential guidance for managing treatment-related side effects. By demonstrating that high-dose, precisely targeted radiation can be safely delivered alongside chemotherapy, Dr. Mislmani has expanded the therapeutic arsenal for advanced gynecologic cancers, helping to transform palliative care. His meticulous toxicity analyses and dose-finding studies continue to inform clinical protocols, making him a key contributor to the advancement of stereotactic body radiotherapy in women’s oncology.
Research Focus
Key Achievements
Top Papers
- 1
- 2